Leaving aside why a 2022 report took until April 2024 to be released...
Report Highlights:
A 6.4% increase in the total number of samples (including urine, non-ABP blood and dried blood spot samples) analyzed and reported into ADAMS in 2022 (256,770) vs. 2021 (241,430);
An increase in the total percentage of AAFs year on year;
An increase in the total number of samples analyzed and reported by most WADA-accredited laboratories and WADA-approved laboratories into ADAMS in 2022 vs 2021.
An increase in the total number and percentage of non-ABP blood and DBS samples analyzed in 2022.
An increase of 1.4% in the number of ABP blood samples analyzed in 2022.
An increase in the total number of AAFs and % AAF for ERAs [including erythropoietin (EPO) and other EPO-receptor agonists], GHRFs and GC/C/IRMS tests in 2022.